Citius Pharmaceuticals, Inc. CTXRW 深 滬
已收盤 08-08 16:00:00 美东时间
0.1441
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.1441
- 總市值 1941.04万
- 52周最高 1.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.012
- 委 比 0.00%
- 總股本 1.35亿
- 歷史最高 2.89
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.012
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Pharmaceuticals Announces LYMPHIR Commercialization Plans
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On October ...
10-24 05:29
Citius Pharmaceuticals Secures $6M in Stock Offering
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On October 20, 2025...
10-22 05:00
Citius Oncology Announced It Has Finalized An Exclusive Agreement With EVERSANA To Support The Q4 2025 U.S. Commercialization Of LYMPHIR
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapyCRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius
10-16 20:52
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
Citius Oncology To Raise $9M In Registered Direct Offering Of 5.14M Shares At $1.75 Each, Plus Warrants For 5.14M Shares Exercisable At $1.84
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and
09-09 20:47
Citius Oncology prices $9 million offering; shares down over 5%
Citius Oncology (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR), announced on Tuesday that it has entered into a securities purchase agreement with a single inst...
09-09 20:42
Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targeting and engagementCRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc.
08-22 20:49
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
08-14 00:16
Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
